{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:39:32Z","timestamp":1792600772013,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MET amplification, although detected in only 2%-5% of intrahepatic cholangiocarcinomas (ICC), represents an actionable oncogenic driver. Treatment options after failure of first-line immunochemotherapy remain limited, and clinical data on vebreltinib, a novel highly selective MET inhibitor, in this molecular subset are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>A 61-year-old woman with metastatic ICC harboring high-level MET amplification (tissue gene copy number, 26.79) experienced disease progression on first-line durvalumab plus gemcitabine\/cisplatin, second-line liposomal irinotecan\/fluorouracil plus lenvatinib and durvalumab, radiotherapy, and transarterial chemoembolization. Following a brief period of vebreltinib (200\u2009mg twice daily) plus durvalumab that was interrupted by grade 4 myelosuppression, the patient continued on vebreltinib monotherapy after hematologic recovery. Restaging computed tomography demonstrated a partial response (PR), with carbohydrate antigen 19-9 normalizing (a 99.2% reduction). This response lasted over 6 months until eventual disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To our knowledge, this is the first report of vebreltinib monotherapy inducing a deep and durable partial response in heavily pretreated, MET-amplified ICC, with the response lasting over 6 months despite eventual disease progression. This case underscores the critical value of comprehensive molecular profiling after first-line treatment failure to identify actionable drivers such as MET amplification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag409","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:35:40Z","timestamp":1791891340000},"source":"Crossref","is-referenced-by-count":0,"title":["Durable response to vebreltinib in heavily pretreated\n                    <i>MET<\/i>\n                    -amplified intrahepatic cholangiocarcinoma: a case report"],"prefix":"10.1093","volume":"31","author":[{"given":"Yingying","family":"Hang","sequence":"first","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Chinese Medicine , Nanjing 210029,","place":["China"]},{"name":"The First Clinical Medical College, Nanjing University of Chinese Medicine , Nanjing 210023,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Chinese Medicine , Nanjing 210029,","place":["China"]},{"name":"Jiangsu Collaborative Innovation Center of TCM Cancer Prevention and Treatment , Nanjing 210023,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiquan","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Chinese Medicine , Nanjing 210029,","place":["China"]},{"name":"The First Clinical Medical College, Nanjing University of Chinese Medicine , Nanjing 210023,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Chinese Medicine , Nanjing 210029,","place":["China"]},{"name":"Jiangsu Collaborative Innovation Center of TCM Cancer Prevention and Treatment , Nanjing 210023,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fufeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Geneseeq Research Institute, Nanjing Geneseeq Technology Inc , Nanjing 210032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Geneseeq Research Institute, Nanjing Geneseeq Technology Inc , Nanjing 210032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Chinese Medicine , Nanjing 210029,","place":["China"]},{"name":"Jiangsu Collaborative Innovation Center of TCM Cancer Prevention and Treatment , Nanjing 210023,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Chinese Medicine , Nanjing 210029,","place":["China"]},{"name":"Jiangsu Collaborative Innovation Center of TCM Cancer Prevention and Treatment , Nanjing 210023,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, Affiliated Hospital of Nanjing University of Chinese Medicine , Nanjing 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5111-4429","authenticated-orcid":false,"given":"Jun","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Chinese Medicine , Nanjing 210029,","place":["China"]},{"name":"The First Clinical Medical College, Nanjing University of Chinese Medicine , Nanjing 210023,","place":["China"]},{"name":"Jiangsu Collaborative Innovation Center of TCM Cancer Prevention and Treatment , Nanjing 210023,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"2026102111473278600_oyag409-B1","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.21037\/jgo-24-165","article-title":"Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"2026102111473278600_oyag409-B2","doi-asserted-by":"crossref","first-page":"e1187","DOI":"10.1097\/SLA.0000000000003788","article-title":"Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis","volume":"274","author":"Zhang","year":"2021","journal-title":"Ann Surg"},{"key":"2026102111473278600_oyag409-B3","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Oh DY, He AR, Qin S, et al. Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","year":"2025","journal-title":"J Hepatol"},{"key":"2026102111473278600_oyag409-B4","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"2026102111473278600_oyag409-B5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026102111473278600_oyag409-B6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026102111473278600_oyag409-B7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/jgh.70208","article-title":"Systemic therapy for advanced biliary tract cancers in 2026: current standard of care and emerging therapeutic strategies","volume":"41","author":"Yoon","year":"2026","journal-title":"J Gastroenterol Hepatol"},{"key":"2026102111473278600_oyag409-B8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours\u2013molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2026102111473278600_oyag409-B9","doi-asserted-by":"crossref","first-page":"e1051","DOI":"10.1093\/oncolo\/oyae076","article-title":"EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance","volume":"29","author":"Kim","year":"2024","journal-title":"Oncologist"},{"key":"2026102111473278600_oyag409-B10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s12672-025-02930-4","article-title":"Response to crizotinib in advanced intrahepatic cholangiocarcinoma with ZKSCAN1-MET fusion and MET amplification: case reports and literature review","volume":"16","author":"Wu","year":"2025","journal-title":"Discov Oncol"},{"key":"2026102111473278600_oyag409-B11","doi-asserted-by":"crossref","first-page":"1254026","DOI":"10.3389\/fonc.2023.1254026","article-title":"Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature review","volume":"13","author":"Zhou","year":"2023","journal-title":"Front Oncol"},{"key":"2026102111473278600_oyag409-B12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/15384047.2022.2029128","article-title":"Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature","volume":"23","author":"Lefler","year":"2022","journal-title":"Cancer Biol Ther"},{"key":"2026102111473278600_oyag409-B13","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/oncolo\/oyae265","article-title":"Exceptional sustained long-term complete response to tepotinib in a MET-amplified advanced intrahepatic biliary tract cancer failing durvalumab plus cisplatin and gemcitabine","volume":"29","author":"Reichinger","year":"2024","journal-title":"Oncologist"},{"key":"2026102111473278600_oyag409-B14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12029-025-01384-9","article-title":"MET amplification in gallbladder cancer: a case report on a precision medicine approach with glumetinib and envafolimab","volume":"57","author":"Wu","year":"2026","journal-title":"J Gastrointest Cancer"},{"key":"2026102111473278600_oyag409-B15","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-24-1726","article-title":"Antitumor activity of vebreltinib and characterization of clinicogenomic features in solid tumors with MET rearrangements","volume":"15","author":"Nakazawa","year":"2025","journal-title":"Cancer Discov"},{"key":"2026102111473278600_oyag409-B16","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.23.02363","article-title":"Vebreltinib for advanced non\u2013small cell lung cancer harboring c-met exon 14 skipping mutation: a multicenter, single-arm, phase II KUNPENG study","volume":"42","author":"Yang","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026102111473278600_oyag409-B17","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.21037\/tlcr-20-1113","article-title":"A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations","volume":"10","author":"Santarpia","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"2026102111473278600_oyag409-B18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-14-0450","article-title":"MET amplification status in therapy-na\u00efve adeno- and squamous cell carcinomas of the lung","volume":"21","author":"Schildhaus","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026102111473278600_oyag409-B19","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14\u2013mutated non\u2013small cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102111473278600_oyag409-B20","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026102111473278600_oyag409-B21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","article-title":"Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer","volume":"82","author":"Hwang","year":"2025","journal-title":"J Hepatol"},{"key":"2026102111473278600_oyag409-B22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s40425-019-0692-z","article-title":"Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade","volume":"7","author":"Liu","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag409\/71921005\/oyag409.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag409\/71921005\/oyag409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag409\/71921005\/oyag409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:47:40Z","timestamp":1792597660000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag409\/8914817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag409","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,10,7]]},"article-number":"oyag409"}}